Semler Scientific to Report Q2 2025 Earnings
Summary
Semler Scientific (NASDAQ:SMLR) is set to announce its Q2 2025 earnings on August 4, with analysts predicting a loss of $0.27 per share and revenue of $8.10 million. The company previously reported a loss of $0.76 per share for Q1 2025. Semler’s stock has seen significant fluctuations, with a market cap of $525.12 million and a consensus rating of ‘moderate buy’ from analysts. Recent institutional investments have increased, indicating growing interest in the company. Market Beat
Impact Analysis
- Business Overview Analysis
- business_model: Semler Scientific operates in the medical device industry, providing diagnostic and monitoring products for chronic diseases. Their primary revenue stream comes from sales and licensing of their products to healthcare providers.
- market_position: Semler holds a niche market position with their specialized devices for chronic disease management. They face competition from larger medical device companies but have carved out a specific segment for their innovative products.
- recent_events_impact: The company has been involved in preliminary settlement discussions with the DOJ, which may affect their financial outlook and market perception. Additionally, increased institutional investment suggests confidence in the company’s future prospects. GlobeNewswire
- Financial Statement Analysis
- income_statement: Analysts predict a revenue of $8.10 million for Q2 2025, compared to a loss of $0.76 per share in Q1 2025, reflecting a potential improvement. The trend in revenue growth and margin will be crucial to assess.
- balance_sheet: Details on assets, liabilities, and working capital are not provided, but it’s important to monitor the asset quality and liability structure in the upcoming report.
- cash_flow: The information on operational cash generation, investment needs, and financing activities is not provided, but evaluating these aspects will be essential once the financial statements are released.
Key financial ratios will need to be calculated from the reported data to assess profitability (ROE, ROA, Operating Margins), liquidity (Current Ratio, Quick Ratio), solvency (Debt/Equity, Interest Coverage), and efficiency (Asset Turnover, Inventory Turnover) once full financial details are available.
